October, 2025
October 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B
Aug 30, 2025, 14:39

Michael Makris Shares French Regulatory Update: Marstacimab (Hympavzi) Not Recommended for Severe Haemophilia A or B

Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on Linkedin:

“Interesting development from France. The French authorities assessed marstacimab (Hympavzi) and concluded that it has no place in the therapeutic strategy for severe haemophilia A or B without inhibitors.

They questioned the robustness of the comparative assessment against other approved therapies and pointed to uncertainties in terms of safety.

The document is in French but Google translate does a pretty good job if you do not speak French. I attach the Google translate version of the conclusion. ”

Michael Makris

Check out here for more.

Find more posts on Hemostasis Today.